Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice

Susi Heiden, Nicolas Vignon-Zellweger, Shigeru Masuda, Keiko Yagi, Kazuhiko Nakayama, Masashi Yanagisawa, Noriaki Emoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. Methods: We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5-9) and treated them with pentoxifylline for twelve weeks. Results: TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. Conclusions: Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.

Original languageEnglish (US)
Article numbere88730
JournalPLoS One
Volume9
Issue number2
DOIs
StatePublished - Feb 11 2014

Fingerprint

Pentoxifylline
pentoxifylline
endothelins
Vascular Endothelium
Endothelin-1
endothelium
blood vessels
heart
Constriction
Pressure
heart failure
mice
Heart Failure
shortenings
Cardiomegaly
cardiac output
hypertrophy
Cardiac Myocytes
Echocardiography
Caspase 8

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice. / Heiden, Susi; Vignon-Zellweger, Nicolas; Masuda, Shigeru; Yagi, Keiko; Nakayama, Kazuhiko; Yanagisawa, Masashi; Emoto, Noriaki.

In: PLoS One, Vol. 9, No. 2, e88730, 11.02.2014.

Research output: Contribution to journalArticle

Heiden, Susi ; Vignon-Zellweger, Nicolas ; Masuda, Shigeru ; Yagi, Keiko ; Nakayama, Kazuhiko ; Yanagisawa, Masashi ; Emoto, Noriaki. / Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice. In: PLoS One. 2014 ; Vol. 9, No. 2.
@article{7d591da7507c4989bf2a6cf96089b055,
title = "Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice",
abstract = "Background: Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. Methods: We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5-9) and treated them with pentoxifylline for twelve weeks. Results: TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. Conclusions: Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.",
author = "Susi Heiden and Nicolas Vignon-Zellweger and Shigeru Masuda and Keiko Yagi and Kazuhiko Nakayama and Masashi Yanagisawa and Noriaki Emoto",
year = "2014",
month = "2",
day = "11",
doi = "10.1371/journal.pone.0088730",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice

AU - Heiden, Susi

AU - Vignon-Zellweger, Nicolas

AU - Masuda, Shigeru

AU - Yagi, Keiko

AU - Nakayama, Kazuhiko

AU - Yanagisawa, Masashi

AU - Emoto, Noriaki

PY - 2014/2/11

Y1 - 2014/2/11

N2 - Background: Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. Methods: We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5-9) and treated them with pentoxifylline for twelve weeks. Results: TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. Conclusions: Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.

AB - Background: Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. Methods: We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5-9) and treated them with pentoxifylline for twelve weeks. Results: TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. Conclusions: Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.

UR - http://www.scopus.com/inward/record.url?scp=84895547020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895547020&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0088730

DO - 10.1371/journal.pone.0088730

M3 - Article

C2 - 24523936

AN - SCOPUS:84895547020

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e88730

ER -